<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02518672</url>
  </required_header>
  <id_info>
    <org_study_id>14-108</org_study_id>
    <nct_id>NCT02518672</nct_id>
  </id_info>
  <brief_title>Pro-resolving Effect of MAG-DHA in Cystic Fibrosis (PREMDIC)</brief_title>
  <acronym>PREMDIC</acronym>
  <official_title>Role of DHA Monoglyceride (MAG-DHA) in the Resolution of Pulmonary Inflammation of Patients With Cystic Fibrosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SCF Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Solutex (Spain)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>SCF Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Monoglyceride of DHA (DHA-MAG) is a lipid compound for which intestinal absorption would
      increase the ratio DHA / arachidonic acid (AA) and promote the synthesis of specific
      metabolites involved in the resolution of inflammation.

      The PREMDIC project, initiated at the Centre Hospitalier Universitaire de Sherbrooke, is a
      randomized double-blind study for people with cystic fibrosis (CF) and aims to evaluate
      whether daily supplementation monoglyceride of DHA (a fatty acid omega-3 family) will reduce
      lung inflammation and improve pulmonary function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of the study is:

      To investigate the efficacity of oral administration of MAG-DHA to increase DHA
      bioavailability and reduce lung inflammation of patients with cystic fibrosis

      The specific objectives of the project are :

        -  Determine the effect of MAG-DHA on lipid membranes of the blood mononuclear cells.

        -  Evaluate the effect of MAG-DHA on lung inflammation (determination of Human leukocyte
           elastase and alpha1 antitrypsin complexes : pHLE).

      For this study, 20 cystic fibrosis patients are recruited. Patients are divided into 2 groups
      of 10 and received a daily dose equivalent to 3 g of placebo (sunflower oil) or MAG-DHA.

      The project takes place over a period of 3 months and patients must travel to the research
      center for a total of five visits including recruitment.

      For the 2 groups, DHA ratio / AA is measured in membranes of mononuclear cells. Forced
      expiratory volume in 1 second (FEV1) is determined and pHLE complexes are detected in plasma
      as a marker of inflammation.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lung and systemic inflammation measurement</measure>
    <time_frame>0 and 90 days</time_frame>
    <description>Docosahexaenoic acid (DHA) and metabolites lipid analyses in plasma and red blood cells Human leukocyte elastase and alpha1 antitrypsin complexes detection in plasma Pulmonary function test (spirometry): Forced Expiratory Volume in 1 second (FEV1) and Forced Vital Capacity (FVC) Leukocytes differential cell counts and C reactive protein (CRP) determination level in blood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>follow up of vital signs</measure>
    <time_frame>0 and 90 days</time_frame>
    <description>weight (Kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>follow up of vital signs</measure>
    <time_frame>0 and 90 days</time_frame>
    <description>Body Mass Index (BMI, Kg/cm2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>follow up of vital signs</measure>
    <time_frame>0 and 90 days</time_frame>
    <description>Blood Pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid profile</measure>
    <time_frame>0 and 90 days</time_frame>
    <description>triglycerides (mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid profile</measure>
    <time_frame>0 and 90 days</time_frame>
    <description>cholesterol (mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid profile</measure>
    <time_frame>0 and 90 days</time_frame>
    <description>high density lipoprotein (mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid profile</measure>
    <time_frame>0 and 90 days</time_frame>
    <description>low density lipoprotein (mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatic function</measure>
    <time_frame>0 and 90 days</time_frame>
    <description>measurement of Alanine aminotransferase (ALT) in plasma (U/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatic function</measure>
    <time_frame>0 and 90 days</time_frame>
    <description>measurement of Aspartate aminotransferase (AST) in plasma (U/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatic function</measure>
    <time_frame>0 and 90 days</time_frame>
    <description>measurement of Gamma glutamyl transpeptidase in plasma (U/l)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>MAG-DHA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MAG-DHA 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (sunflower oil) 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MAG-DHA</intervention_name>
    <description>MAG-DHA 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.</description>
    <arm_group_label>MAG-DHA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (sunflower oil) 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. forced expiratory volume in 1 second (FEV1) between 30 - 90%.

          2. no respiratory exacerbations during the last 2 weeks before the start of the study

          3. not have clotting problems or a history of bleeding diathesis

          4. patients with liver function abnormalities are included in the study

        Exclusion Criteria:

          1. pregnant women or those not using contraception.

          2. known allergy to fish and / or seafood.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>André M Cantin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Al-Turkmani MR, Freedman SD, Laposata M. Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis. Prostaglandins Leukot Essent Fatty Acids. 2007 Nov-Dec;77(5-6):309-18. Epub 2007 Nov 26. Review.</citation>
    <PMID>18036797</PMID>
  </reference>
  <reference>
    <citation>Andersson C, Al-Turkmani MR, Savaille JE, Alturkmani R, Katrangi W, Cluette-Brown JE, Zaman MM, Laposata M, Freedman SD. Cell culture models demonstrate that CFTR dysfunction leads to defective fatty acid composition and metabolism. J Lipid Res. 2008 Aug;49(8):1692-700. doi: 10.1194/jlr.M700388-JLR200. Epub 2008 Apr 25.</citation>
    <PMID>18441018</PMID>
  </reference>
  <reference>
    <citation>Cantin A. Cystic fibrosis lung inflammation: early, sustained, and severe. Am J Respir Crit Care Med. 1995 Apr;151(4):939-41.</citation>
    <PMID>7697269</PMID>
  </reference>
  <reference>
    <citation>Dyerberg J, Madsen P, Møller JM, Aardestrup I, Schmidt EB. Bioavailability of marine n-3 fatty acid formulations. Prostaglandins Leukot Essent Fatty Acids. 2010 Sep;83(3):137-41. doi: 10.1016/j.plefa.2010.06.007.</citation>
    <PMID>20638827</PMID>
  </reference>
  <reference>
    <citation>Fortin S, Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof, US819690, 2012, US8222295, 2012.</citation>
  </reference>
  <reference>
    <citation>Fortin S, Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof, CA2672513, 2008, CA2677670, 2010, US8119690, 2011.</citation>
  </reference>
  <reference>
    <citation>Freedman SD, Katz MH, Parker EM, Laposata M, Urman MY, Alvarez JG. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice. Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13995-4000.</citation>
    <PMID>10570187</PMID>
  </reference>
  <reference>
    <citation>Mimoun M, Coste TC, Lebacq J, Lebecque P, Wallemacq P, Leal T, Armand M. Increased tissue arachidonic acid and reduced linoleic acid in a mouse model of cystic fibrosis are reversed by supplemental glycerophospholipids enriched in docosahexaenoic acid. J Nutr. 2009 Dec;139(12):2358-64. doi: 10.3945/jn.109.110999. Epub 2009 Oct 14.</citation>
    <PMID>19828687</PMID>
  </reference>
  <reference>
    <citation>Morin C, Fortin S, Cantin AM, Rousseau E. Docosahexaenoic acid derivative prevents inflammation and hyperreactivity in lung: implication of PKC-Potentiated inhibitory protein for heterotrimeric myosin light chain phosphatase of 17 kD in asthma. Am J Respir Cell Mol Biol. 2011 Aug;45(2):366-75. doi: 10.1165/rcmb.2010-0156OC. Epub 2010 Nov 5.</citation>
    <PMID>21057106</PMID>
  </reference>
  <reference>
    <citation>Morin C, Fortin S, Cantin AM, Sirois M, Sirois C, Rizcallah E, Rousseau É. Anti-cancer effects of a new docosahexaenoic acid monoacylglyceride in lung adenocarcinoma. Recent Pat Anticancer Drug Discov. 2013 Sep;8(3):319-34.</citation>
    <PMID>23092161</PMID>
  </reference>
  <reference>
    <citation>Panchaud A, Sauty A, Kernen Y, Decosterd LA, Buclin T, Boulat O, Hug C, Pilet M, Roulet M. Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial. Clin Nutr. 2006 Jun;25(3):418-27. Epub 2005 Dec 2.</citation>
    <PMID>16325968</PMID>
  </reference>
  <reference>
    <citation>Pier G, Prince A, Cantin A. Cystic fibrosis: an-ion transport issue? Nat Med. 2011 Feb;17(2):166-7. doi: 10.1038/nm0211-166.</citation>
    <PMID>21297610</PMID>
  </reference>
  <reference>
    <citation>Vij N, Mazur S, Zeitlin PL. CFTR is a negative regulator of NFkappaB mediated innate immune response. PLoS One. 2009;4(2):e4664. doi: 10.1371/journal.pone.0004664. Epub 2009 Feb 27.</citation>
    <PMID>19247502</PMID>
  </reference>
  <results_reference>
    <citation>Cantin AM, Bilodeau G, Larivée P, Richter MV. Plasma biomarkers and cystic fibrosis lung disease. Clin Invest Med. 2012 Jul 4;35(4):E173-81.</citation>
    <PMID>22863555</PMID>
  </results_reference>
  <results_reference>
    <citation>Morin C, Cantin AM, Rousseau É, Sirois M, Sirois C, Rizcallah E, Fortin S. Proresolving Action of Docosahexaenoic Acid Monoglyceride in Lung Inflammatory Models Related to Cystic Fibrosis. Am J Respir Cell Mol Biol. 2015 Oct;53(4):574-83. doi: 10.1165/rcmb.2014-0223OC.</citation>
    <PMID>25781052</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2015</study_first_submitted>
  <study_first_submitted_qc>August 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2015</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

